VEGF with AMD3100 endogenously mobilizes mesenchymal stem cells and improves fracture healing

J Orthop Res. 2019 Jun;37(6):1294-1302. doi: 10.1002/jor.24164. Epub 2018 Nov 30.

Abstract

A significant number of fractures develop non-union. Mesenchymal stem cell (MSC) therapy may be beneficial, however, this requires cell acquisition, culture and delivery. Endogenous mobilization of stem cells offers a non-invasive alternative. The hypothesis was administration of VEGF and the CXCR4 antagonist AMD3100 would increase the circulating pool of available MSCs and improve fracture healing. Ex-breeder female wistar rats received VEGF followed by AMD3100, or sham PBS. Blood prepared for culture and colonies were counted. P3 cells were analyzed by flow cytometry, bi-differentiation. The effect of mobilization on fracture healing was evaluated with 1.5 mm femoral osteotomy stabilized with an external fixator in 12-14 week old female Wistars. The mobilized group had significantly greater number of cfus/ml compared to controls, p = 0.029. The isolated cells expressed 1.8% CD34, 35% CD45, 61% CD29, 78% CD90, and differentiated into osteoblasts but not into adipocytes. The fracture gap in animals treated with VEGF and AMD3100 showed increased bone volume; 5.22 ± 1.7 µm3 and trabecular thickness 0.05 ± 0.01 µm compared with control animals (4.3 ± 3.1 µm3 , 0.04 ± 0.01 µm, respectively). Radiographic scores quantifying fracture healing (RUST) showed that the animals in the mobilization group had a higher healing score compared to controls (9.6 vs. 7.7). Histologically, mobilization resulted in significantly lower group variability in bone formation (p = 0.032) and greater amounts of bone and less fibrous tissue than the control group. Clinical significance: This pre-clinical study demonstrates a beneficial effect of endogenous MSC mobilization on fracture healing, which may have translation potential to prevent or treat clinical fractures at risk of delayed or non-union fractures. © 2018 The Authors. Journal of Orthopaedic Research® Published by Wiley Periodicals, Inc. on behalf of Orthopaedic Research Society. J Orthop Res 37:1294-1302, 2019.

Keywords: AMD3100; VEGF; fracture healing; mesenchymal stem cells; mobilization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzylamines
  • Cell Movement / drug effects
  • Chemokine CXCL12 / physiology
  • Cyclams
  • Female
  • Femoral Fractures / diagnostic imaging
  • Femoral Fractures / physiopathology
  • Femoral Fractures / therapy*
  • Fracture Healing / drug effects*
  • Heterocyclic Compounds / pharmacology*
  • Mesenchymal Stem Cells / drug effects*
  • Mesenchymal Stem Cells / physiology
  • Rats
  • Rats, Wistar
  • Receptors, CXCR4 / antagonists & inhibitors
  • Receptors, CXCR4 / physiology
  • Vascular Endothelial Growth Factor A / pharmacology*
  • X-Ray Microtomography

Substances

  • Benzylamines
  • CXCL12 protein, human
  • Chemokine CXCL12
  • Cxcr4 protein, rat
  • Cyclams
  • Heterocyclic Compounds
  • Receptors, CXCR4
  • Vascular Endothelial Growth Factor A
  • plerixafor